MuriPhys connects CNS delivery, behavioral assays and electrophysiology for research on neurodegenerative diseases. Define the model, therapeutic mechanism and endpoints so the evidence addresses a specific development question.
Research on Huntington’s disease, Parkinson’s disease, ALS and ataxia can connect delivery with selected motor, cognitive and physiological endpoints. The study plan defines the relevant features of the model and the evidence needed for the next decision.
Diseases We Specialize In:
Huntington’s Disease
MuriPhys provides specialized tools to investigate the progressive neuronal degeneration characteristic of Huntington’s. Our intraparenchymal (IPa) drug delivery directly targets the striatum and cortex, key regions affected by the disease. Complementing this, we offer behavioral assessments such as rotarod, balance beam, and Y-maze, alongside electrophysiological studies (EEG, EMG) to track disease markers and therapeutic efficacy at every stage. Read More.
Ataxia
Ataxia research benefits from MuriPhys’ targeted delivery to the cerebellar cortex and deep nuclei. Our array of behavioral tests assesses gait, balance, and motor coordination, while electrophysiological recordings track cerebellar activity and disease evolution. Read More.
Parkinson’s disease research can combine intraparenchymal delivery to the substantia nigra with study-appropriate ICV or IT approaches. Behavioral assays assess selected motor features, while EEG and EMG can provide relevant brain and neuromuscular readouts. Parkinson’s Disease Read More.
ALS research can incorporate CNS delivery, including IPa and ICV approaches, alongside motor and functional assessments. Open-field testing and other model-appropriate assays can characterize activity and motor changes. OCT is an ocular imaging option when the study includes an appropriate eye-related question. Amyotrophic Lateral Sclerosis (ALS) Read More.
Dementias
From Alzheimer’s to Lewy Body and Frontotemporal Dementia, MuriPhys provides comprehensive tools to dissect the complexities of cognitive decline. Our drug delivery platforms span intraparenchymal, ICV, and IT routes, facilitating localized and systemic targeting. Behavioral assays explore memory and learning, while EEG recordings highlight neuronal dysfunction, offering crucial biomarkers for early detection and progression tracking.
Why MuriPhys?
- CNS Delivery: Select IPa, ICV, IT or another appropriate route for the anatomical target, formulation and study objective.
- Behavioral Assays: Choose cognitive and motor assessments that measure defined features of the selected model.
- Electrophysiology: EEG and EMG provide distinct brain and neuromuscular measurements when relevant to the study.
- Tailored Solutions: We customize our services to align with the unique demands of your research, offering scalable, adaptable models that reflect the intricacies of each neurodegenerative condition.
Explore our full suite of neurodegenerative models and services. Together, we shape the future of neurological therapeutics.